Recent Updates on Treatment of Uveal Melanoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 15 July 2025 | Viewed by 218
Special Issue Editors
Interests: melanoma; early phase drug development
Interests: melanoma; treatment; therapy
Special Issue Information
Dear Colleagues,
Uveal melanoma is a rare malignancy originating from melanocytes within the uveal tract. Despite advancements in early diagnosis, localized treatments, and more recently, systemic treatment of metastatic disease, the prognosis for patients with metastatic uveal melanoma remains generally poor. In this Special Issue, we aim to expand our understanding and amplify the latest research and developments in the treatment of uveal melanoma, addressing current challenges and exploring novel approaches. We invite the submission of original research articles, reviews, and clinical studies that focus on various aspects of treatment for uveal melanoma. Potential topics of interest include, but are not limited to, the following:
- Innovations in surgical techniques, radiotherapy, and systemic therapies;
- Genetic and molecular insights into treatment responses;
- Translational research bridging biological behavior with potential clinical implications.
We look forward to receiving your contributions.
Dr. Richard D. Carvajal
Dr. Shaheer Khan
Dr. Brian Peter Marr
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- uveal melanoma
- systemic therapies
- surgical innovations
- radiotherapy
- genetic and molecular insights
- translational research
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
